NOBILIS TRT LIVE

Nazione: Irlanda

Lingua: inglese

Fonte: HPRA (Health Products Regulatory Authority)

Principio attivo:

TURKEY RHINOTRACHEITIS VIRUS STRAIN BUT1#8544

Commercializzato da:

Intervet Ireland Limited

Codice ATC:

QI01AD01

INN (Nome Internazionale):

TURKEY RHINOTRACHEITIS VIRUS STRAIN BUT1#8544

Dosaggio:

Unknown

Forma farmaceutica:

Lyophilisate for suspension

Tipo di ricetta:

POM

Gruppo terapeutico:

Fowl - Chicken, Fowl - Turkey

Area terapeutica:

Avian rhinotracheitis virus vaccine

Indicazioni terapeutiche:

Immunological - Live Vaccine

Stato dell'autorizzazione:

Authorised

Data dell'autorizzazione:

2002-12-16

Scheda tecnica

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobilis TRT Live
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE
Live turkey rhinotracheitis (TRT) virus, strain BUT 1#8544
10
2.5
TCID
50
* per dose
* TCID
50
: 50 % tissue culture infective dose
EXCIPIENTS
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Lyophilisate for suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Chickens (broilers) and turkeys.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the active immunisation of broilers and turkeys from one day of age to reduce clinical signs of rhinotracheitis virus
infection.
Onset of immunity: 3 weeks after vaccination.
Duration of immunity: 6 – 9 weeks after vaccination.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Only vaccinate healthy birds. Sick or weak birds will not develop adequate immunity following vaccination.
A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system.
Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status,
genetic factors, concurrent drug therapy and stress. Under certain conditions, for example extreme disease pressure,
fully immune birds may succumb to disease. Therefore, successful vaccination may not be synonymous with full
protection in the face of a disease challenge.
Immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration.
Do not use chlorinated water.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 09/02/2016_
_CRN 7022595_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions�